Core Laboratories stock falls 2.49 percent as earnings risks persist

Published on 09/22/2026 at 19:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Core Laboratories stock closed at USD 10.97 on September 21, 2026, down 31.5 percent year to date. Q2 revenue fell 4.3 percent year over year.

CLB, NL0015000CZ2, Illustration mit AI erstellt.

Core Laboratories stock (ISIN NL0015000CZ2) closed at USD 10.97 on the NYSE on September 21, 2026, down 2.49 percent from the prior close. The price stood 31.5 percent below its January 1, 2026 level of USD 16.02, while the company reported second-quarter EPS of USD 0.11 on July 29, 2026.

Stock remains below yearly high

The latest market data place CLB within a 52-week range of USD 9.79 to USD 20.36. Its market capitalization was USD 503.36 million and trading volume reached 661,073 shares as of September 21, 2026, compared with average volume of 440,231 shares.

The valuation picture is divided. Core Laboratories traded at a trailing price-to-earnings ratio of 19.59, while the same market data show a consensus price target of USD 21.00. That target is 91.4 percent above the September 21 closing price, although the company has been covered by only two analysts in the previous 90 days.

Second quarter shows pressure

According to Yahoo Finance on September 22, 2026, second-quarter Production Enhancement revenue increased 15 percent sequentially and 5 percent year over year, while operating margins reached 12 percent. The improvement contrasts with a 9 percent year-over-year decline in Reservoir Description revenue and a 5 percent operating margin in that segment.

The latest quarterly EPS of USD 0.11 exceeded the consensus estimate of USD 0.09 by USD 0.02, according to MarketBeat in its September 22, 2026 company overview. Revenue nevertheless declined 4.3 percent from the comparable quarter, leaving the stronger Production Enhancement trend offset by weakness in Reservoir Description.

Cash flow and geopolitics matter

First-half operating cash flow declined to USD 11.8 million from USD 20.6 million in the prior-year period, while operating capital expenditure rose to USD 8.1 million from USD 6.3 million, according to Yahoo Finance on September 22, 2026. The cash-flow comparison is important because the company is simultaneously funding capital spending, dividends and share repurchases.

The same report states that roughly 80 percent of Reservoir Description revenue is tied to projects originating outside the United States. Geopolitical disruption in the Middle East and the Russia-Ukraine region has delayed projects, reduced customer activity and weakened utilization, creating a direct counterweight to technology adoption and a possible recovery in international offshore work.

CLB closes near the lower range

Core Laboratories stock closed at USD 10.97 on the NYSE as of September 21, 2026, with the session range at USD 10.84 to USD 11.25. The dated market figures place the stock much closer to its 52-week low of USD 9.79 than to its 52-week high of USD 20.36.